Does ageing influence deep brain stimulation outcomes in Parkinson's disease?
Identifieur interne : 001539 ( Istex/Corpus ); précédent : 001538; suivant : 001540Does ageing influence deep brain stimulation outcomes in Parkinson's disease?
Auteurs : Fabienne Ory-Magne ; Christine Brefel-Courbon ; Marion Simonetta-Moreau ; Nelly Fabre ; Jean Albert Lotterie ; Patrick Chaynes ; Isabelle Berry ; Yves Lazorthes ; Olivier RascolSource :
- Movement Disorders [ 0885-3185 ] ; 2007-07-30.
English descriptors
- KwdEn :
Abstract
We sought to define the influence of ageing in clinical, cognitive, and quality‐of‐life outcomes after subthalamic nucleus deep brain stimulation (STN‐DBS) in Parkinson's disease (PD). We performed motor assessment (UPDRS), mood tests, cognitive, and quality of life evaluation (PDQ‐39) on PD patients before surgery, and 12 and 24 months after, and we recorded adverse events. The variations of these parameters after surgery were correlated with age using regression statistical tests. Cerebral bleeding risk was evaluated by a nonparametric test. We enrolled 45 patients (mean age 60 ± 9 years, range 40–73). No significant correlation was found between age and motor scores and PDQ‐39 improvements at 12 months. At 24 months, there was a significant negative correlation between age and the improvement of three dimensions of PDQ 39 (mobility, activities of daily life, and cognition). Cognitive impairment showed no correlation, but apathy and depression were positively correlated with age. Significant statistical difference was observed between cerebral bleeding and age. STN‐DBS is an effective treatment for elderly patients with advanced PD. A longer follow‐up duration and a larger population seem necessary to better assess the quality of life perception in elderly patients and to determinate the real risk of hemorrage. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21547
Links to Exploration step
ISTEX:63A8968FEA436962FC372E504B0D82DCFA1382D7Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Does ageing influence deep brain stimulation outcomes in Parkinson's disease?</title><author><name sortKey="Ory Agne, Fabienne" sort="Ory Agne, Fabienne" uniqKey="Ory Agne F" first="Fabienne" last="Ory-Magne">Fabienne Ory-Magne</name><affiliation><mods:affiliation>Department of Neurology, University Hospital CHU, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name><affiliation><mods:affiliation>Department of Neurology, University Hospital CHU, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Simonetta Oreau, Marion" sort="Simonetta Oreau, Marion" uniqKey="Simonetta Oreau M" first="Marion" last="Simonetta-Moreau">Marion Simonetta-Moreau</name><affiliation><mods:affiliation>Department of Neurology, University Hospital CHU, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Fabre, Nelly" sort="Fabre, Nelly" uniqKey="Fabre N" first="Nelly" last="Fabre">Nelly Fabre</name><affiliation><mods:affiliation>Department of Neurology, University Hospital CHU, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Lotterie, Jean Albert" sort="Lotterie, Jean Albert" uniqKey="Lotterie J" first="Jean Albert" last="Lotterie">Jean Albert Lotterie</name><affiliation><mods:affiliation>Department of Nuclear Medicine, University Hospital CHU, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Chaynes, Patrick" sort="Chaynes, Patrick" uniqKey="Chaynes P" first="Patrick" last="Chaynes">Patrick Chaynes</name><affiliation><mods:affiliation>Department of Neurosurgery, University Hospital CHU, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Berry, Isabelle" sort="Berry, Isabelle" uniqKey="Berry I" first="Isabelle" last="Berry">Isabelle Berry</name><affiliation><mods:affiliation>Department of Nuclear Medicine, University Hospital CHU, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Lazorthes, Yves" sort="Lazorthes, Yves" uniqKey="Lazorthes Y" first="Yves" last="Lazorthes">Yves Lazorthes</name><affiliation><mods:affiliation>Department of Neurosurgery, University Hospital CHU, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Department of Neurology, University Hospital CHU, Toulouse, France</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:63A8968FEA436962FC372E504B0D82DCFA1382D7</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21547</idno><idno type="url">https://api.istex.fr/document/63A8968FEA436962FC372E504B0D82DCFA1382D7/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001539</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Does ageing influence deep brain stimulation outcomes in Parkinson's disease?</title><author><name sortKey="Ory Agne, Fabienne" sort="Ory Agne, Fabienne" uniqKey="Ory Agne F" first="Fabienne" last="Ory-Magne">Fabienne Ory-Magne</name><affiliation><mods:affiliation>Department of Neurology, University Hospital CHU, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Brefel Ourbon, Christine" sort="Brefel Ourbon, Christine" uniqKey="Brefel Ourbon C" first="Christine" last="Brefel-Courbon">Christine Brefel-Courbon</name><affiliation><mods:affiliation>Department of Neurology, University Hospital CHU, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Simonetta Oreau, Marion" sort="Simonetta Oreau, Marion" uniqKey="Simonetta Oreau M" first="Marion" last="Simonetta-Moreau">Marion Simonetta-Moreau</name><affiliation><mods:affiliation>Department of Neurology, University Hospital CHU, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Fabre, Nelly" sort="Fabre, Nelly" uniqKey="Fabre N" first="Nelly" last="Fabre">Nelly Fabre</name><affiliation><mods:affiliation>Department of Neurology, University Hospital CHU, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Lotterie, Jean Albert" sort="Lotterie, Jean Albert" uniqKey="Lotterie J" first="Jean Albert" last="Lotterie">Jean Albert Lotterie</name><affiliation><mods:affiliation>Department of Nuclear Medicine, University Hospital CHU, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Chaynes, Patrick" sort="Chaynes, Patrick" uniqKey="Chaynes P" first="Patrick" last="Chaynes">Patrick Chaynes</name><affiliation><mods:affiliation>Department of Neurosurgery, University Hospital CHU, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Berry, Isabelle" sort="Berry, Isabelle" uniqKey="Berry I" first="Isabelle" last="Berry">Isabelle Berry</name><affiliation><mods:affiliation>Department of Nuclear Medicine, University Hospital CHU, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Lazorthes, Yves" sort="Lazorthes, Yves" uniqKey="Lazorthes Y" first="Yves" last="Lazorthes">Yves Lazorthes</name><affiliation><mods:affiliation>Department of Neurosurgery, University Hospital CHU, Toulouse, France</mods:affiliation></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><mods:affiliation>Department of Neurology, University Hospital CHU, Toulouse, France</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-07-30">2007-07-30</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1457">1457</biblScope><biblScope unit="page" to="1463">1463</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">63A8968FEA436962FC372E504B0D82DCFA1382D7</idno><idno type="DOI">10.1002/mds.21547</idno><idno type="ArticleID">MDS21547</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>age</term><term>deep brain stimulation</term><term>subthalamic nucleus</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We sought to define the influence of ageing in clinical, cognitive, and quality‐of‐life outcomes after subthalamic nucleus deep brain stimulation (STN‐DBS) in Parkinson's disease (PD). We performed motor assessment (UPDRS), mood tests, cognitive, and quality of life evaluation (PDQ‐39) on PD patients before surgery, and 12 and 24 months after, and we recorded adverse events. The variations of these parameters after surgery were correlated with age using regression statistical tests. Cerebral bleeding risk was evaluated by a nonparametric test. We enrolled 45 patients (mean age 60 ± 9 years, range 40–73). No significant correlation was found between age and motor scores and PDQ‐39 improvements at 12 months. At 24 months, there was a significant negative correlation between age and the improvement of three dimensions of PDQ 39 (mobility, activities of daily life, and cognition). Cognitive impairment showed no correlation, but apathy and depression were positively correlated with age. Significant statistical difference was observed between cerebral bleeding and age. STN‐DBS is an effective treatment for elderly patients with advanced PD. A longer follow‐up duration and a larger population seem necessary to better assess the quality of life perception in elderly patients and to determinate the real risk of hemorrage. © 2007 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Fabienne Ory‐Magne MD</name><affiliations><json:string>Department of Neurology, University Hospital CHU, Toulouse, France</json:string></affiliations></json:item><json:item><name>Christine Brefel‐Courbon MD</name><affiliations><json:string>Department of Neurology, University Hospital CHU, Toulouse, France</json:string></affiliations></json:item><json:item><name>Marion Simonetta‐Moreau MD, PhD</name><affiliations><json:string>Department of Neurology, University Hospital CHU, Toulouse, France</json:string></affiliations></json:item><json:item><name>Nelly Fabre MD</name><affiliations><json:string>Department of Neurology, University Hospital CHU, Toulouse, France</json:string></affiliations></json:item><json:item><name>Jean Albert Lotterie MD</name><affiliations><json:string>Department of Nuclear Medicine, University Hospital CHU, Toulouse, France</json:string></affiliations></json:item><json:item><name>Patrick Chaynes MD, PhD</name><affiliations><json:string>Department of Neurosurgery, University Hospital CHU, Toulouse, France</json:string></affiliations></json:item><json:item><name>Isabelle Berry MD, PhD</name><affiliations><json:string>Department of Nuclear Medicine, University Hospital CHU, Toulouse, France</json:string></affiliations></json:item><json:item><name>Yves Lazorthes MD, PhD</name><affiliations><json:string>Department of Neurosurgery, University Hospital CHU, Toulouse, France</json:string></affiliations></json:item><json:item><name>Olivier Rascol MD, PhD</name><affiliations><json:string>Department of Neurology, University Hospital CHU, Toulouse, France</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>age</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>deep brain stimulation</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>subthalamic nucleus</value></json:item></subject><language><json:string>eng</json:string></language><abstract>We sought to define the influence of ageing in clinical, cognitive, and quality‐of‐life outcomes after subthalamic nucleus deep brain stimulation (STN‐DBS) in Parkinson's disease (PD). We performed motor assessment (UPDRS), mood tests, cognitive, and quality of life evaluation (PDQ‐39) on PD patients before surgery, and 12 and 24 months after, and we recorded adverse events. The variations of these parameters after surgery were correlated with age using regression statistical tests. Cerebral bleeding risk was evaluated by a nonparametric test. We enrolled 45 patients (mean age 60 ± 9 years, range 40–73). No significant correlation was found between age and motor scores and PDQ‐39 improvements at 12 months. At 24 months, there was a significant negative correlation between age and the improvement of three dimensions of PDQ 39 (mobility, activities of daily life, and cognition). Cognitive impairment showed no correlation, but apathy and depression were positively correlated with age. Significant statistical difference was observed between cerebral bleeding and age. STN‐DBS is an effective treatment for elderly patients with advanced PD. A longer follow‐up duration and a larger population seem necessary to better assess the quality of life perception in elderly patients and to determinate the real risk of hemorrage. © 2007 Movement Disorder Society</abstract><qualityIndicators><score>6.222</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1367</abstractCharCount><pdfWordCount>3786</pdfWordCount><pdfCharCount>23850</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>203</abstractWordCount></qualityIndicators><title>Does ageing influence deep brain stimulation outcomes in Parkinson's disease?</title><genre><json:string>Serial article</json:string></genre><host><volume>22</volume><pages><total>7</total><last>1463</last><first>1457</first></pages><issn><json:string>0885-3185</json:string></issn><issue>10</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/mds.21547</json:string></doi><id>63A8968FEA436962FC372E504B0D82DCFA1382D7</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/63A8968FEA436962FC372E504B0D82DCFA1382D7/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/63A8968FEA436962FC372E504B0D82DCFA1382D7/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/63A8968FEA436962FC372E504B0D82DCFA1382D7/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Does ageing influence deep brain stimulation outcomes in Parkinson's disease?</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2007</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Does ageing influence deep brain stimulation outcomes in Parkinson's disease?</title><author><persName><forename type="first">Fabienne</forename><surname>Ory‐Magne</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Service de Neurologie, CHU Purpan, Place du Dr Baylac 31059 Toulouse Cedex, France</p></note><affiliation>Department of Neurology, University Hospital CHU, Toulouse, France</affiliation></author><author><persName><forename type="first">Christine</forename><surname>Brefel‐Courbon</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, University Hospital CHU, Toulouse, France</affiliation></author><author><persName><forename type="first">Marion</forename><surname>Simonetta‐Moreau</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Department of Neurology, University Hospital CHU, Toulouse, France</affiliation></author><author><persName><forename type="first">Nelly</forename><surname>Fabre</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Neurology, University Hospital CHU, Toulouse, France</affiliation></author><author><persName><forename type="first">Jean Albert</forename><surname>Lotterie</surname><roleName type="degree">MD</roleName></persName><affiliation>Department of Nuclear Medicine, University Hospital CHU, Toulouse, France</affiliation></author><author><persName><forename type="first">Patrick</forename><surname>Chaynes</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Department of Neurosurgery, University Hospital CHU, Toulouse, France</affiliation></author><author><persName><forename type="first">Isabelle</forename><surname>Berry</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Department of Nuclear Medicine, University Hospital CHU, Toulouse, France</affiliation></author><author><persName><forename type="first">Yves</forename><surname>Lazorthes</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Department of Neurosurgery, University Hospital CHU, Toulouse, France</affiliation></author><author><persName><forename type="first">Olivier</forename><surname>Rascol</surname><roleName type="degree">MD, PhD</roleName></persName><affiliation>Department of Neurology, University Hospital CHU, Toulouse, France</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-07-30"></date><biblScope unit="vol">22</biblScope><biblScope unit="issue">10</biblScope><biblScope unit="page" from="1457">1457</biblScope><biblScope unit="page" to="1463">1463</biblScope></imprint></monogr><idno type="istex">63A8968FEA436962FC372E504B0D82DCFA1382D7</idno><idno type="DOI">10.1002/mds.21547</idno><idno type="ArticleID">MDS21547</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>We sought to define the influence of ageing in clinical, cognitive, and quality‐of‐life outcomes after subthalamic nucleus deep brain stimulation (STN‐DBS) in Parkinson's disease (PD). We performed motor assessment (UPDRS), mood tests, cognitive, and quality of life evaluation (PDQ‐39) on PD patients before surgery, and 12 and 24 months after, and we recorded adverse events. The variations of these parameters after surgery were correlated with age using regression statistical tests. Cerebral bleeding risk was evaluated by a nonparametric test. We enrolled 45 patients (mean age 60 ± 9 years, range 40–73). No significant correlation was found between age and motor scores and PDQ‐39 improvements at 12 months. At 24 months, there was a significant negative correlation between age and the improvement of three dimensions of PDQ 39 (mobility, activities of daily life, and cognition). Cognitive impairment showed no correlation, but apathy and depression were positively correlated with age. Significant statistical difference was observed between cerebral bleeding and age. STN‐DBS is an effective treatment for elderly patients with advanced PD. A longer follow‐up duration and a larger population seem necessary to better assess the quality of life perception in elderly patients and to determinate the real risk of hemorrage. © 2007 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>age</term></item><item><term>deep brain stimulation</term></item><item><term>subthalamic nucleus</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2006-12-18">Received</change><change when="2007-04-01">Registration</change><change when="2007-07-30">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/63A8968FEA436962FC372E504B0D82DCFA1382D7/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="100"><doi origin="wiley" registered="yes">10.1002/mds.v22:10</doi><numberingGroup><numbering type="journalVolume" number="22">22</numbering><numbering type="journalIssue">10</numbering></numberingGroup><coverDate startDate="2007-07-30">30 July 2007</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="130" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21547</doi><idGroup><id type="unit" value="MDS21547"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2007 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2006-12-18"></event><event type="manuscriptRevised" date="2007-04-01"></event><event type="manuscriptAccepted" date="2007-04-01"></event><event type="publishedOnlineEarlyUnpaginated" date="2007-05-21"></event><event type="firstOnline" date="2007-05-21"></event><event type="publishedOnlineFinalForm" date="2007-07-23"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1457</numbering><numbering type="pageLast">1463</numbering></numberingGroup><correspondenceTo>Service de Neurologie, CHU Purpan, Place du Dr Baylac 31059 Toulouse Cedex, France</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21547.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="3"></count><count type="referenceTotal" number="31"></count><count type="wordTotal" number="4325"></count></countGroup><titleGroup><title type="main" xml:lang="en">Does ageing influence deep brain stimulation outcomes in Parkinson's disease?</title><title type="short" xml:lang="en">Ageing Deep Brain Stimulation Outcomes in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Fabienne</givenNames><familyName>Ory‐Magne</familyName><degrees>MD</degrees></personName><contactDetails><email normalForm="ory.f@chu-toulouse.fr">ory.f@chu‐toulouse.fr</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Christine</givenNames><familyName>Brefel‐Courbon</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Marion</givenNames><familyName>Simonetta‐Moreau</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Nelly</givenNames><familyName>Fabre</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Jean Albert</givenNames><familyName>Lotterie</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Patrick</givenNames><familyName>Chaynes</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Isabelle</givenNames><familyName>Berry</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Yves</givenNames><familyName>Lazorthes</familyName><degrees>MD, PhD</degrees></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Olivier</givenNames><familyName>Rascol</familyName><degrees>MD, PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="FR" type="organization"><unparsedAffiliation>Department of Neurology, University Hospital CHU, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="FR" type="organization"><unparsedAffiliation>Department of Nuclear Medicine, University Hospital CHU, Toulouse, France</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="FR" type="organization"><unparsedAffiliation>Department of Neurosurgery, University Hospital CHU, Toulouse, France</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">age</keyword><keyword xml:id="kwd2">deep brain stimulation</keyword><keyword xml:id="kwd3">subthalamic nucleus</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>We sought to define the influence of ageing in clinical, cognitive, and quality‐of‐life outcomes after subthalamic nucleus deep brain stimulation (STN‐DBS) in Parkinson's disease (PD). We performed motor assessment (UPDRS), mood tests, cognitive, and quality of life evaluation (PDQ‐39) on PD patients before surgery, and 12 and 24 months after, and we recorded adverse events. The variations of these parameters after surgery were correlated with age using regression statistical tests. Cerebral bleeding risk was evaluated by a nonparametric test. We enrolled 45 patients (mean age 60 ± 9 years, range 40–73). No significant correlation was found between age and motor scores and PDQ‐39 improvements at 12 months. At 24 months, there was a significant negative correlation between age and the improvement of three dimensions of PDQ 39 (mobility, activities of daily life, and cognition). Cognitive impairment showed no correlation, but apathy and depression were positively correlated with age. Significant statistical difference was observed between cerebral bleeding and age. STN‐DBS is an effective treatment for elderly patients with advanced PD. A longer follow‐up duration and a larger population seem necessary to better assess the quality of life perception in elderly patients and to determinate the real risk of hemorrage. © 2007 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Does ageing influence deep brain stimulation outcomes in Parkinson's disease?</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Ageing Deep Brain Stimulation Outcomes in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Does ageing influence deep brain stimulation outcomes in Parkinson's disease?</title></titleInfo><name type="personal"><namePart type="given">Fabienne</namePart><namePart type="family">Ory‐Magne</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University Hospital CHU, Toulouse, France</affiliation><description>Correspondence: Service de Neurologie, CHU Purpan, Place du Dr Baylac 31059 Toulouse Cedex, France</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Christine</namePart><namePart type="family">Brefel‐Courbon</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University Hospital CHU, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marion</namePart><namePart type="family">Simonetta‐Moreau</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, University Hospital CHU, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Nelly</namePart><namePart type="family">Fabre</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Neurology, University Hospital CHU, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jean Albert</namePart><namePart type="family">Lotterie</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Department of Nuclear Medicine, University Hospital CHU, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Patrick</namePart><namePart type="family">Chaynes</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurosurgery, University Hospital CHU, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Isabelle</namePart><namePart type="family">Berry</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Nuclear Medicine, University Hospital CHU, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Yves</namePart><namePart type="family">Lazorthes</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurosurgery, University Hospital CHU, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Olivier</namePart><namePart type="family">Rascol</namePart><namePart type="termsOfAddress">MD, PhD</namePart><affiliation>Department of Neurology, University Hospital CHU, Toulouse, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007-07-30</dateIssued><dateCaptured encoding="w3cdtf">2006-12-18</dateCaptured><dateValid encoding="w3cdtf">2007-04-01</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">2</extent><extent unit="tables">3</extent><extent unit="references">31</extent><extent unit="words">4325</extent></physicalDescription><abstract lang="en">We sought to define the influence of ageing in clinical, cognitive, and quality‐of‐life outcomes after subthalamic nucleus deep brain stimulation (STN‐DBS) in Parkinson's disease (PD). We performed motor assessment (UPDRS), mood tests, cognitive, and quality of life evaluation (PDQ‐39) on PD patients before surgery, and 12 and 24 months after, and we recorded adverse events. The variations of these parameters after surgery were correlated with age using regression statistical tests. Cerebral bleeding risk was evaluated by a nonparametric test. We enrolled 45 patients (mean age 60 ± 9 years, range 40–73). No significant correlation was found between age and motor scores and PDQ‐39 improvements at 12 months. At 24 months, there was a significant negative correlation between age and the improvement of three dimensions of PDQ 39 (mobility, activities of daily life, and cognition). Cognitive impairment showed no correlation, but apathy and depression were positively correlated with age. Significant statistical difference was observed between cerebral bleeding and age. STN‐DBS is an effective treatment for elderly patients with advanced PD. A longer follow‐up duration and a larger population seem necessary to better assess the quality of life perception in elderly patients and to determinate the real risk of hemorrage. © 2007 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>age</topic><topic>deep brain stimulation</topic><topic>subthalamic nucleus</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>10</number></detail><extent unit="pages"><start>1457</start><end>1463</end><total>7</total></extent></part></relatedItem><identifier type="istex">63A8968FEA436962FC372E504B0D82DCFA1382D7</identifier><identifier type="DOI">10.1002/mds.21547</identifier><identifier type="ArticleID">MDS21547</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2007 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001539 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001539 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:63A8968FEA436962FC372E504B0D82DCFA1382D7
|texte= Does ageing influence deep brain stimulation outcomes in Parkinson's disease?
}}
| This area was generated with Dilib version V0.6.23. |  |